Company
Every investor coverage indicates participated in a round Duke University School of Medicine raised.
Companies Duke University School of Medicine acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Terry Kim | Professor of Ophthalmology | Brandon BioCatalyst portfolio |
Stories naming Duke University School of Medicine. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Eye-drug developer Azura Ophthalmics, working from Melbourne and Tel Aviv, has assembled a seven-member scientific advisory board of ophthalmology specialists to guide clinical development of its lead candidate AZR-MD-001.